Category : Orthopedic Oncology / Orthopaedics
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma,
Source : Medical Xpress
On : 08-May-2026